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c-myc as an inducer of polycystic kidney disease in transgenic mice. In
this study, a genetic model of polycystic kidney disease (PKD) has been
produced in transgenic mice bearing the murine c-myc gene driven by
the SV4O enhancer and the adult /3-globin promoter. These animals
reproducibly develop PKD and die of renal failure. The phenotype
appears to result from the overexpression of c-myc in the renal tubular
epithelium and consequent abnormal cell proliferation. These trans-
genic mice represent a genetic model of PKD which bears similarities to
human autosomal dominant PKD (ADPKD) with respect to renal
morphology, renal functional alterations and dominant transmission.
Study of these transgenic mice may offer valuable insights into the
pathogenesis of PKD.
Polycystic kidney disease (PKD) is the most common human
genetically transmitted disease. PKD occurs in a recessive
infantile form as well as an autosomal dominant adult form
(ADPKD) displaying variable penetrance. The autosomal dom-
inant transmission, the lack of a definitive genetic screening test
and the typical clinical onset in the third decade of life explain
the high prevalence of ADPKD in the population [I]. Although
the genetic defect(s) responsible for ADPKD has not been
identified, at least two loci have been implicated, one close to
the a-globin locus on chromosome 16 [2] and a second locus
that appears to be unlinked to a-globin 113, 41.
The etiology of PKD is unknown, and no means of prevention
or cure for this disease exists. Three pathogenetic mechanisms
have been proposed to explain the origin of cysts from the renal
tubular epithelium: an increase in tubular cell proliferation, an
alteration in tubular basement membrane production and an
extratubular or intratubular obstruction of the nephron [11.
Although a causal relationship between renal cysts, epithelial
hyperplasia and renal malignancies has been proposed [51,
definitive evidence has been lacking.
There has been an intensive search for animal models of
PKD. In many species, renal cystic lesions can be induced by a
variety of chemical agents such as glucocorticoids [6, 7]. These
chemically induced models suggest that environmental factors
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may play a significant role in the development of renal cysts.
However their relevance to inherited forms of PKD and their
value for studies of the genetic basis of the human disease are
unclear. A mouse model closely resembling the recessive,
infantile form of PKD was provided by the discovery of the
spontaneous mutant "congenital polycystic kidney" (cpk).
However, no genetic models for adult ADPKD have been
reported.
In this paper, we describe the production of a transgenic
mouse model that bears a number of similarities to human adult
ADPKD. The transgenic mice carry a fusion gene including the
c-myc coding region, the /3-globin promoter and the simian virus
40 (SV4O) enhancer, which is expressed at high levels in the
renal tubular epithelium. These animals reproducibly develop
renal morphological and functional alterations characteristic of
PKD, and die of renal failure.
Methods
Production and analysis of transgenic mice
The hybrid SBM gene construct was produced by linking the
human adult /3-globin promoter contained in a Sphl-Ncol
fragment (687 nucleotides) of 5' flanking DNA to a Xbal-
BamHl fragment of the mouse c-myc gene (exon 2, exon 3 and
3' flanking sequences) in a BLUESCRIPT vector (Fig. 1).
Sequence analysis showed that the resulting construct included
the first 39 nt of the 5' untranslated region of the adult /3-globin
gene, and the last 30 nucleotides of intron 1 of the c-myc gene,
thereby creating a CCTCAGACT junction. In addition, SV4O
enhancer sequences were ligated upstream of the /3-globin
sequences. The SV4O DNA from —270 to —95 nucleotides was
obtained from a BamH 1 fragment of plasmid pMT3SVE [81
including both 72 bp repeats but not the 21 bp repeats. In the
second construct (BBM) the SV4O enhancer [9] was replaced by
the /3-globin enhancer [10—12] situated in the 3' flanking se-
quence contained within the BstNl fragment [10] from 425 to
1480 nucleotides downstream of the human adult /3-globin
polyadenylation site. This enhancer was linked directly up-
stream to the f3-globin promoter. The resulting BBM construct
conserved the same junction sequence between the /3-globin
promoter and mouse c-myc gene fragment and was inserted
within a pUC19 vector.
A Sall-Xbal fragment for the SBM construct and a Sall-
BamHl fragment for the BBM construct were excised from
these plasmids, isolated by agarose gel electrophoresis and
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purified by centrifugation on CsCI gradients [13]. The SBM and
BBM fragments were microinjected into the pronuclei of
(C57BL/6J x CBA/J)F2 fertilized eggs. Transgenic founder
mice and progeny were identified by Southern blot analysis of
DNA obtained from tail tissue.
Isolation of RNA from transgenic mouse tissues
Tissues were obtained from sacrificed or autopsied animals,
and portions of each were used for histologic studies and for
RNA analysis. RNA was isolated by the LiCI-urea method of
Auffray and Rougeon [14] or by the GuSCN method of Chirg-
win et al [15], The integrity of all RNA preparation was
monitored by electrophoresis on formaldehyde-agarose gels.
Analysis of SBM mRNA levels
RNase protection. An "SBM probe" was produced to detect
the mRNA from the transgene (Fig. 1). A BalI-PstI fragment
containing the /3-globin/c-myc junction (Fig. 3) was subcloned
into pSP64 (Promega) and used to synthesize an antisense RNA
probe, the "SBM" probe. Each RNA sample was hybridized
with a uniformly 32P-labelled RNA produced [161 from the
"SBM probe", digested with RNase and electrophoresed on a
urea-polyacrylamide gel, from which an autoradiograph was
produced [13].
In situ hybridization. Hybridization techniques were per-
formed on Bouin's-fixed, paraffin-embedded renal tissue. Sec-
tions (3 ) were collected on 3-aminopropyl triethoxy silane
coated slides [17]. Each section was hybridized with a uni-
formly 35S-labelied antisense RNA produced from the "SBM
probe", washed and coated with Kodak NTB-II emulsion for
autoradiography [18, 191. Photographs were taken using dark
field optics (Fig. 4).
Histology
Tissues from all organs were fixed in Bouin's solution and
embedded in paraffin (Fig. 2). Three micron thick sections of
kidney were stained with hematoxylin and eosin, periodic acid
Schiff (PAS), Masson's trichrome and Jones Methenamine
silver.
Results
Our original intent in these studies was to express a c-myc
transgene in the erythroid cells of developing mice, in an
attempt to perturb the normal erythroid cell differentiation
process. For this purpose, we produced two hybrid genes
containing regulatory elements of the human adult f3-globin
gene and the coding region of the genomic c-myc proto-
oncogene. A DNA fragment containing the c-myc coding region
(exon 2 and exon 3), but lacking any known transcriptional
regulatory elements [20], was joined to the adult f3-globin
promotor. The fusion gene produced lacked the /3-globin trans-
lation initiation site, but contained the initiation site for the
c-myc protein (Fig. 1). In one construct (BBM; not shown), the
enhancer situated in the 3' flanking sequence of the human adult
/3-globin gene [10—12] was appended to the globin-c-myc fusion
gene. In the other construct (SBM; Fig. 1), the SV4O enhancer
[9] was substituted for the 3-globin enhancer.
Fifteen transgenic founders (that is, the original transgenic
mice developed from microinjected eggs) carrying multiple
copies of BBM were produced, and neither they nor their
transgenic progeny displayed any phenotypic abnormalities or
increased frequencies of tumorigenesis over a period of two
years. In contrast, the transgenic mice carrying SBM consis-
tently developed PKD. From 22 founder mice, 18 transgenic
lines were derived, all carrying one to thirty copies of the SBM
construct as determined by Southern analysis (Table 1). A total
of 37 SBM transgenic mice representing the 18 transgenic lines
were subjected to complete histologic analysis. All thirty-seven
transgenic animals displayed PKD, while non-transgenic litter-
mates never developed the disease. Within weeks of birth, the
affected mice developed muscular atrophy, runting, hyperven-
tilation and lethargy. Death due to renal failure ensued by six
weeks to three months of age. Renal function was monitored by
measurements of blood urinary nitrogen (BUN) and serum
creatinine. At 12 weeks of age BUN was 281 59 mg/dl (normal
20 mg/dl for (C57B1/6J x CBA/J)Fl), and creatinine was 1.4
0.4 mg/dl (normal < 0.1 mgldl). The mice were anemic with
hematocrit 8 to 15% (normal 40%), a common finding in chronic
renal failure.
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Fig. 1. SBM construct used to generate transgenic mice. SV4O enhancer sequences (dark circle) were linked to the human adult /3-globin promoter
and 5' flanking DNA (stippled) and to the mouse c-myc gene (solid bar, introns and 3' flanking region; hatched boxes, exons 2 and 3) contained
in a BLUESCRIPT vector (thin line). Restriction map of the SBM construct is provided. The SV4O enhancer was inserted into the BamHI site
upstream of the junction fragment /3-globinlc-myc gene. X, XbaI Se, Spel; B, BamHI; Sm, Smal, P. PstI; E, EcoRl; Sp, SphI; K, KpnI; S, Sail;
E', EcoRY; H, Hindlil; C, Clal.
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Fig. 2. A. Laparotomy of a transgenic mouse. Both kidneys are markedly and uniformly enlarged with numerous macroscopic cysts studding the
cortical surfaces. B. Early cystic disease in a transgenic mouse sacrificed at 10 days of age. Scattered discrete cysts are present in the cortex and
medulla. (Hematoxylin and eosin, x 32). C. Papillary hyperplasia of a cystic renal tubule from a transgenic mouse (Hematoxylin and eosin x 200).
D. Microadenoma (arrowheads) in the kidney of a transgenic mouse (10 days of age) with early polycystic kidney disease. E. Most cysts are lined
by a single layer of cuboidal epithelial cells. There is focal segmental globmeruloscierosis (arrow). (Jones Methenamine silver, x 200). F. The renal
cortex of a transgenic mouse contains tubular cysts adjacent to a perivascular infiltrate of atypical plasma cells (arrow). The cytologic features of
the niyeloma cells are depicted in the inset (Hematoxylin and eosin x 80, inset X 320). Production of this color figure was sponsored by Abbott
Laboratories Ltd., Montréal, Québec, Canada.
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Table 1. Genetic characteristics and renal abnormali
transgenic mice
ties in adult
SBM line
# Transgene
copies
# Mice # With cystic
analyzed disease
# With
atypical
plasma cell
infiltrates
9
14
19
20
34
45
46
47
48
58
59
74
75
78
81
83
95
97
10
30
1
20
1
7
15
30
1
10
10
10
5
10
20
20
25
5
3 3
2 2
2 2
4 4
1 1
1 1
2 2
2 2
1 1
2 2
3 3
1 1
4 4
1 1
4 4
1 1
1 1
2 2
2
1
2
4
1
1
1
2
1
2
3
1
4
1
4
1
0
1
Total 37 37 32
a mosaic transgenic founder
The kidneys were generally more than twofold enlarged
compared to age matched controls and displayed multicystic
bosselated cortical surfaces (Fig. 2A). By gross examination,
the cysts were bilateral and diffuse, affecting both the cortex
and medulla. On histologic examination, there were multiple
cortical and medullary cysts, some containing proteinaceous
casts (Fig. 2B). A spectrum of cystic hyperplasia and papillary
hyperplasia was present in most mice (Fig. 2C) and a few
contained renal epithelial microadenomas (Fig. 2D). With ad-
vanced disease, focal segmental and global glomerulosclerosis
and interstitial fibrosis were also observed (Fig. 2E). In view of
the frequent association of renal cysts with cysts of liver and
pancreas and cerebral aneurysms in human PKD, liver, pan-
creas and brain of all 37 transgenic mice were examined grossly
and histologically. No hepatic or pancreatic cysts were de-
tected, nor were cerebral aneurysms observed.
In 80% of the adult SBM transgenic mice examined, the
kidneys also contained focal interstitial aggregates of cytologi-
cally atypical plasma cells with focal binucleated forms sugges-
tive of possible myeloma (Fig. 2F, Table 1). In most animals the
kidneys were the sole or predominant organ affected. However,
in a small percentage of mice, more generalized involvement of
lymphoid organs by these atypical plasma cell infiltrates was
also observed. Although nonspecific interstitial lymphocytic
infiltrates may occur surrounding renal cysts in human adult
PKD [21], monomorphic atypical plasma cell infiltrates have
not been described. It is noteworthy that the development of
PKD preceded the appearance of atypical plasmacytic infil-
trates in the kidneys, indicating that renal cysts are not a
consequence of these infiltrates: of 15 transgenic mice exam-
ined histologically between birth and 20 days of age, 13 showed
PKD (Table 2) while none showed any evidence of plasma cell
infiltrates.
To investigate the role of the SBM transgene in the develop-
ment of this specific phenotype, we examined the level of
globinlc-myc mRNA in various organs of the transgenic mice.
When analyzed by Northern analysis (data not shown), RNA
from the kidneys of SBM transgenic mice contained a 2.1 kb
transcript that hybridized with a c-myc probe. This RNA was
approximately the size expected for the globin/c-myc fusion
RNA, and was smaller than the normal, endogeneous c-myc
RNA seen in RNA from a pre-B cell line (2.4 kb).
Transcripts were studied in more detail by RNase protection
analysis (Fig. 3). The SBM probe (Fig. 3) was derived from the
junction region of the globin/c-myc fusion gene, so that mRNA
initiated at the normal /3-globin cap site in the fusion gene
should protect a 208 nt fragment, while endogenous c-myc
mRNA should protect a 137 nt fragment corresponding to
exon 2 sequences. Positive control RNA from a pre-B and a
MOPC I 04-E cell line (which has a truncated c-myc gene trans-
located from the first intron to the immunoglobulin heavy-chain
locus [ref. 22]), protected the expected 137 nt fragment, as well
as a 165 nt fragment (Fig. 3). The latter presumably represents
transcripts initiated at the c-myc P3 promoter or other cryptic
promoters in intron I of c-myc [23—25], or unspliced precursor
RNA. Either of these RNAs, which lack /3-globin sequences,
will only hybridize to the 165 nt portion of the probe derived
from the c-myc gene (p0 in Fig. 3).
Control RNA from kidneys of a non-transgenic mouse (Fig.
3; lane Fl) did not contain detectable c-myc mRNA, which is
consistent with published data [26]. In transgenic mice, high
levels of c-myc expression were observed in the kidneys, while
levels in the other tissues were generally much lower or
undetectable (Fig. 3). The predominant band seen in transgenic
kidney RNA was 165 nt rather than the expected 208 nt. This is
most likely explained by transcriptional initiation at a novel cap
site created by the juxtaposition of globin and myc sequences in
the transgene. This hypothesis is further supported by the
junction sequence (CCTCAGACT) which correlates with the
creation of a consensus sequence that may act as an initiator
[271. Although this band is indistinguishable in size from the 165
nt band seen in control pre-B cell and MOPC RNAs, the fact
that it is specifically elevated in the transgenic mouse tissues
makes it unlikely that this band represents a transcript of the
endogeneous c-myc gene. RNA from several tissues also pro-
tected smaller amounts of a 137 nt fragment which probably
represents normally spliced mRNA from the endogenous c-myc
gene. Our experiments clearly demonstrate that SBM trans-
genic kidneys contain markedly elevated levels of c-myc
mRNA, in comparison to other transgenic organs and normal
mouse kidney controls.
The presence of atypical plasma cell infiltrates in the kidneys
of many animals suggested that the transgene is also expressed
in certain lymphoid cells, since c-myc overexpression is known
to cause lymphoid neoplasia [28—301. However, normal lym-
phoid tissues (spleen and bone marrow) from all but one of the
mice examined (SBM2O-2; Fig. 3) showed very low levels of the
165 nucleotide band, suggesting that the transgene may be
expressed in only a small subset of lymphoid cells.
To more precisely localize the site of elevated c-myc expres-
sion within the kidneys, we examined normal and transgenic
kidneys by in situ hybridization using the SBM probe. The
hybridization signal was localized specifically to the epithelial
lining of cystic and hyperplastic tubules (Fig. 4), as well as to
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Table 2. Renal morphologic features in young transgenic mice
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Fig. 3. RNase protection analysis qf SBM murine tissues. Six trans-
genie lines, and controls including normal Fl mouse kidney, a pre-B cell
line (300-19P) and a plasmacytoma cell line (MOPC 104-E) were
analyzed. The RNA samples consisted of 10 sg from each mouse tissue,
5 and 10 g from the preB cell line and 5 jsg from the plasmacytoma cell
line. Organs studied include: kidney (K), liver (L), spleen (S), bone
marrow (BM), lung (Lu), blood (Bl). M, molecular weight marker. p,
RNA probe (Ball-Pstl fragment of the SBM fusion gene, and used for
analysis of the SBM mRNAs); pe, protected fragment expected if
initiation occurred at /3.globin cap site; p0, protected fragment observed
in transgenic mice, and in pre-B and MOPC control RNAs (165
nucleotides); pm, protected fragment resulting from correctly spliced
endogeneous myc transcript (137 nucleotides).
the atypical plasma cell infiltrates; no hybridization above
background was seen in normal controls or BBM transgenic
kidneys (data not shown).
Discussion
This paper describes the production and characterization of a
novel transgenic mouse model of polycystic kidney disease.
The animals carried a fusion gene, SBM, consisting of a
Fig. 4. Detection of c-myc mRNA by in situ hybridization in transgenic
SBM kidney tissue. Intense signal is present over the epithelial cells
lining the tubular cysts.
combination of regulatory elements from the SV4O enhancer
and /3-globin promotor joined to the coding portion of the
murine c-myc gene. This SBM fusion gene has resulted in
elevated c-myc expression in the kidneys of developing trans-
genie mice. The overexpression of c-myc in the renal tubular
epithelium appears to trigger cyst formation, resulting in a renal
disease with many similarities to human ADPKD. These mice
display markedly enlarged kidneys, extensive bilateral cysts,
progressive glomeruloscierosis, tubular epithelial hyperplasia
and occasional renal tubular microadenomas. While c-myc is
best known for its oncogenic potential, this work demonstrates
that the proto-oncogene may also play an important role in
certain non-neoplastic genetic diseases.
Particularly striking is the 100% penetrance of the PKD
phenotype in the SBM transgenic mice. Since similar renal
changes occurred in all 18 independent transgenic lines, and
preferential expression of the transgene in kidney was seen in
all of the seven lines tested, this pattern of expression cannot be
due to a chromosomal "position effect", that is, a consequence
of the site of integration of the transgene into the mouse
genome. Rather it appears to be a function of regulatory
sequences in the SBM construct. While the SV4O enhancer
sequences contain an element shown to be preferentially active
# Progeny Tubular
analyzed____________ Age cysts
#Progeny with
Tubular
hyperplasiaSBM line
14
20
75
Total 15 13 10 0
Atypical plasma
cell infiltrates
2 Newborn 1 0 0
2 Sdays 1 0 0
1 7days 1 1 0
4 lOdays 4 4 0
1 l5days 1 1 0
1 Newborn 1 0 0
2 lOdays 2 2 0
1 lsdays
2odays
1
1
1
1
0
0
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in CV! kidney epithelial cells (PvuII core sequence [311), the
entire SV4O enhancer has been shown to be active in many cell
types in vitro [31, 32] and in a variety of tissues in transgenic
mice [33, 34]. Perhaps the novel coupling of 3-globin promoter
sequences and the SV4O enhancer in the SBM construct mod-
ifies the tissue-specificity of the enhancer, causing restriction of
its activity to certain cell types. The unique combination of
regulatory elements in the SBM construct probably interacts
with particular renal factor(s) to cause c-myc expression and
result in profound biological consequences.
Transgenic mice carrying the complete SV4O early region
encoding the small and large T antigen (Tag), display a pheno-
type characterized by choroid plexus tumors leading to death
by three or four months of age [33, 34]. Renal abnormalities,
including focal segmental glomerulosclerosis and tubular cysts,
were also found in the majority of these animals [35]. However,
the renal pathology in these mice was generally mild and did not
lead to renal failure [33, 36, 37]. In contrast, the SBM mice
succumb to renal failure in early adulthood and do not develop
tumors of the choroid plexus. Thus, both morphologically and
functionally the SBM transgenic mouse model more closely
resembles human PKD. Similarities between the disease seen in
the SBM mice and the adult dominant form of human PKD
include: the dominant transmission of the disease, the forma-
tion of bilateral diffusely distributed renal cysts, the hyperplasia
of the renal tubular epithelium, and progressive renal functional
deterioration leading to renal failure. The onset of renal failure
in adulthood is roughly comparable to human ADPKD, given
the difficulty of comparing the rate of aging in humans and mice,
The mouse model differs from human ADPKD in that the
extrarenal manifestations of ADPKD have not been observed in
the mouse model, the transgenic mice display complete pene-
trance of the PKD phenotype, and some transgenic kidneys also
contain atypical plasma cell infiltrates. Overall, while the SBM
mouse model is not a perfect model for human ADPKD, it more
closely resembles this disease than any previously available
animal model.
The spontaneous mouse mutant cpk has been proposed as a
model for the recessive, infantile form of human PKD [38—40].
An elevated level of endogeneous c-myc mRNA has been
observed in the kidneys of mice homozygous for the cpk
mutation, although the mechanism by which the recessive cpk
mutation stimulates c-rnyc is unknown [41]. By itself, the
observation of elevated c-myc expression in the cpk mouse
kidney was insufficient to establish a causal relationship be-
tween myc expression and the PKD phenotype. However the
ability of the SBM transgene to confer a dominant form of PKD
in mice clearly demonstrates that c-myc overexpression is a
sufficient event to directly or indirectly trigger the development
of renal cysts.
As high levels of c-myc are thought to promote cell prolifer-
ation [20], both the observation of elevated c-myc expression in
the cpk mice and the phenotype of the SBM transgenic mice are
consistent with a role for increased tubular cell proliferation in
the development of PKD, In particular, the specific localization
of c-myc expression to the tubular epithelia of renal cysts, and
the finding of associated tubular epithelial hyperplasia in the
SBM transgenic mice strongly suggest that cyst formation can
arise through the deregulation of tubular epithelial cell prolifer-
ation.
Our results support the idea that the elevated renal expres-
sion of c-myc or of a related proto-oncogene, may play a role in
the development of one or more forms of human PKD. The
heterogeneity observed among the different types of PKD
suggests that the primary genetic defect may occur in more than
one gene. Because the infantile form of PKD is inherited as a
recessive trait, the primary genetic defect in this case is more
likely to involve a mutation causing "loss-of-function", rather
than the overexpression of a gene (which would more likely
result in a dominant trait). However, it may result from a
deficient gene which triggers a series of events ultimately
resulting in the overexpression of c-myc or a related gene.
Hence, c-myc may be one of several genes that is abnormally
expressed in human PKD.
In conclusion, we have shown that the expression of a c-myc
transgene in the kidney is a sufficient event to trigger the
development of severe PKD and renal failure in SBM trans-
genic mice, Further study of this novel transgenic model of
PKD may provide valuable insights into the pathogenesis and
possible prevention of this highly prevalent human inherited
disease.
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